DIADIA0.41%
SPYSPY0.21%
QQQQQQ0.04%
Trending
Top trending tickerGRRRGRRR18.32%
NVTSNVTS22.97%
GMEGME9.35%
USARUSAR5.15%
MRVLMRVL10.13%
AVGOAVGO2.27%
SOXSSOXS4.25%
PANWPANW3.53%
CMGCMG1.74%
TGTXTGTX3.68%
Top trending tickerGRRRGRRR18.32%
NVTSNVTS22.97%
GMEGME9.35%
USARUSAR5.15%
MRVLMRVL10.13%
AVGOAVGO2.27%
SOXSSOXS4.25%
PANWPANW3.53%
CMGCMG1.74%
TGTXTGTX3.68%
INCY logo

INCYIncyte Corp.

$92.20
$0.04
(0.04%)
Pre-Market
Updated: 08:37 AM EDT·Prev Close $92.24
EarningsJul 28
Mkt Cap$18.43B
Vol150.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

News
all
press releases
Incytes Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi/Minjuvi) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi/Minjuvi), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide...
Business Wire
News Placeholder
More News
News Placeholder
Why Is Agios Pharmaceuticals (AGIO) Up 8.6% Since Last Earnings Report?
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Here's Why Incyte (INCY) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
News Placeholder
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 8:40 a.m. EDT. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About...
Business Wire
News Placeholder
Here's Why Incyte (INCY) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
News Placeholder
Why Incyte (INCY) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
News Placeholder
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
Incyte (Nasdaq:INCY) and Genesis Molecular AI today announced a significant expansion of their strategic collaboration building and deploying state-of-the-art AI to accelerate the discovery of novel molecules for collaboration targets selected by Incyte. The expanded agreement is among the first...
Business Wire
News Placeholder
Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development
Incyte (Nasdaq:INCY) and Edison Scientific today announced a strategic collaboration to employ Kosmos, Edisons AI scientist, for Incytes discovery and development work. This press release features...
Business Wire
News Placeholder
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
Incyte (Nasdaq:INCY) today announced that data from key programs in its Hematology and Oncology franchises will be presented at the European Hematology Association (EHA) 2026 Congress, to be held June 11 - 14, 2026, in Stockholm, Sweden. The breadth of the data that will be showcased at the 2026...
Business Wire
<
1
2
...
>
Top Discussions

Advertisement|Remove ads.